{"id":476980,"date":"2026-05-26T00:00:00","date_gmt":"2026-05-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2025-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast-2\/"},"modified":"2026-06-26T11:20:36","modified_gmt":"2026-06-26T11:20:36","slug":"dlsfop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2026-biopharma-dry-and-wet-age-related-macular-degeneration-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p><abbr title=\"age-related macular degeneration\">AMD<\/abbr> is a leading cause of vision loss across the G7 markets, with wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> accounting for most drug-treated cases. The market is dominated by <abbr title=\"intravitreal\">IVT<\/abbr> therapies such as Avastin, Eylea, Vabysmo, and Eylea <abbr title=\"high-dose\">HD<\/abbr>, while the recent launch of Pavblu, a biosimilar of Eylea, adds competitive pressure. Unmet needs persist, particularly around reducing treatment burden and extending dosing intervals. The anticipated launch of <abbr title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s (e.g., EyePoint\u2019s Duravyu, Ocular Therapeutix\u2019s Axpaxli) and gene therapies (i.e., AbbVie \/ Regenxbio\u2019s sura-vec, Adverum \/ Eli Lilly\u2019s ixo-vec, and 4DMT\u2019s 4D-150), designed to deliver longer-lasting efficacy, is expected to reshape treatment dynamics over the next decade. In parallel, the <abbr title=\"geographic atrophy\">GA<\/abbr> pipeline is active with candidates such as Annexon\u2019s vonaprument and Aviceda\u2019s AVD-104 poised to expand options beyond Syfovre and Izervay for this underserved population. This report provides stakeholders with critical insight into how treatment patterns, competitive pressures, and emerging therapies will influence <abbr title=\"age-related macular degeneration\">AMD<\/abbr> market evolution across G7 countries through 2035.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How will treatment patterns for wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and <abbr title=\"geographic atrophy\">GA<\/abbr> evolve across the G7 markets over the next decade? <\/li>\n<li>What are the unmet needs driving physicians\u2019 prescribing decisions? <\/li>\n<li>How will biosimilars and new entrants impact market share and pricing dynamics? <\/li>\n<li>What factors will shape adoption of emerging therapies in wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and <abbr title=\"geographic atrophy\">GA<\/abbr>? <\/li>\n<li>How will competitive pressures and late-phase developments influence forecast growth?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading retinal specialists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Total prevalence of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and geographic atrophy (<abbr title=\"geographic atrophy\">GA<\/abbr>) by country, including diagnosed\/drug-treated populations<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key dry and wet age-related macular degeneration therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments<\/strong>: Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<p>\u00b7 Optimize your long-term disease and development strategy.<\/p>\n<p>\u00b7 Quantify market potential for your pipeline assets and those of your competitors.<\/p>\n<p>\u00b7 Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/p>\n<p>\u00b7 Gauge the commercial outlook and impact of key market events.<\/p>\n","protected":false},"template":"","class_list":["post-476980","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/476980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=476980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}